Major Initiatives

The Takeda Initiative (2010–Present)

Given the critical role of the private sector in the fight against AIDS, TB, and malaria, one of the central roles that FGFJ plays in Japan is that of a coordinator between the Global Fund and Japanese corporations.

The Takeda Initiative is an excellent example of the Japanese private sector’s commitment to the Global Fund. In June 2019, Takeda Pharmaceutical, a leading global pharmaceutical company based in Japan, announced its renewed partnership with the Global Fund, contributing ¥1 billion (approximately US$9 million) over the next five years. Takeda became the first private sector company to make a financial commitment to the Global Fund’s Sixth Replenishment. The funds will be used to support the improvement of maternal and child health by integrating quality HIV, tuberculosis, and malaria services in antenatal and postnatal care in several priority countries in Africa.

Takeda’s partnership with the Global Fund began in 2010, when it contributed ¥1 billion (approximately US$10 million) from 2010 to 2019 to support strengthening healthcare systems and developing human capacity in Africa. Takeda is one of the first Japanese companies to make such a major financial contribution to address an important global challenge.

Objectives of the Takeda Initiative

Takeda Initiative 2

[2020–2024: Improvement of maternal and child health by integrating quality HIV, TB, and malaria services in antenatal and postnatal care in several priority countries in Africa]

Takeda Initiative 1

[2010–2019: Health system strengthening and human capacity development initiatives in Africa]

  1. To support human capacity development for health system strengthening in developing countries. As the first phase of the initiative, Takeda is supporting the following Global Fund projects in Africa:
  • Tanzania (target disease: malaria)
    National Insecticide Treated Nets Implementation Plan (NATNETS)
    —Strengthening the system for distributing insecticide-treated nets and developing the human resources engaged in promoting the use and dissemination of nets
  • Nigeria (target disease: HIV/AIDS)
    Scale-up of comprehensive HIV/AIDS treatment, care, and support
    — Training of staff members of not-for-profit and grassroots organizations engaged in providing community-based care for HIV/AIDS patients and orphans, and carrying out advocacy and awareness-raising activities
  • Kenya (target disease: tuberculosis)
    Reinforcement of TB control
    — Capacity development for health workers engaged in tuberculosis diagnosis and treatment
  1. To support the Global Fund in its public relations and advocacy activities in Japan

For more information

Global Fund press announcement for 2020–2024 commitment: English / Japanese
Takeda Pharmaceutical Company announcement

Global Fund press announcement for 2010–2019 commitment: English / Japanese
Takeda Pharmaceutical Company announcement


Back